PTSD? OGD
`ages inc use muah BHaTaNT. ONS GAT
`LS, Salva ane Telemark Oiffos U8. OERARTMENT OF COMMERCE
`Linder the Papanwurks Recurtiun Actaf T3R5, ne peroura are Teguted fe rogpard io. a colsctan ev intamnetion untass 8 displays 9 valid OMEcuriea/ number,
`
`SUBSTITUTESTATEMENT
`
`Groumataroas aenmiting aacutios of this aubatiitte stationed
`[] trventor ts daenased,
`[}inventor is andar legal Inowpactty,
`[| venter cannot be found or naaehed alker dtlgent alfert, ar
`inemntor has natiatadt by aecute the aath or dacigration uneler 37 CAR 1.03.
`
`WARNING:
`fPellionsniagmicantis cautlaned ip avold audmiting pansone! iNarmatianik documents HedIn a patent anolowign that may
`tountibasdie to Stanly theft. Rorsanal ifomiation auchan scala! somey nunthers, bank acosuntnumbers, of orsdlt card rueribaes
`tfoiwer than o chiwek or oredll cant suihevinaiion fon PTOMSSS aubotiied for payment purses) le neers aquined by the USPTO
`fe Suppor8 pation OFsn apolication. Hthis typeaf penmonel infortatiie: is Inchated in dooney submited (6fhe USPTS,
`cara id conetierreclantinn HeeaapdaakmahatecichinObsnets berpilcehe So the
`
`
`"T7eeA/SPRA”SECRETARS
`
`Ay pyak ~AineSPVGetal ¢AAS
`
`Shans. aang foind inventors, pleasecheckthe aggronrists box helen
`An appination datesheet under df GPR 178 (PTONARAH4 or emuivaiont) naming the antive mantive enilly has bean
`orfa currently submitted
`oe
`| An anglastion date sheaf under 37 CRRULIPTOUAIANS or aqubadent) has not bean adimitied. Thus, s Subatiuts
`Sinlament Gunglemenial Siwet (PFTOMAIAN f or equivalent} saning the anilInvertiwantliy and preasding inventor
`information & aiushwel, Gas 37 GFR Laeihh
`
`2828 Dupont Drive-T2-7H whe i deeaaned,
`
`CecatingAddressfanlesspmesedt isansopteationdads Sent STORMANSarssanaiene :
`
`: reusedefiigorfloroFhasretisedtoexoculateothordeannur3?CFR 1.5.
`Pageofl
`
`inoapectintedl,
`
`gar
`
`.
`
`EXHIBIT 1004 (Part 5 of 5)
`0784
`
`0784
`
` EXHIBIT 1004 (Part 5 of 5)
`
`

`

`§§°§ws:‘:§* sfistzi §iaiam§3§°:%
`
`gm: w gémn msmn§ in mmmfim
`§<$»§3*§}
`ma Wvaézsg me 3% °i§?s§
`‘%§#‘§‘z*e mama is) :3: Wm: amikamx as“ gtsaféma.
`mm yaw wmsmmvw ma
`wmmt $3 Em smzsiyfimanig ti am; ssxszg mam as ammfi ms‘: {*5}
`geaiemzi as:32“;i‘:s;m‘§: ‘Far m
`m‘ M5 §fi is 3:53 i.§.$y{3‘ 3Es‘_‘h}{;‘E}; {2}
`a~§'&§:§ ifimmafim
`§2§ wimmgr;
`am {3} Em
`gsasmmaa Fm“
`5&5 §?%§3:mx§32§m's is mm? $3; ifim {A3, Qaima am Traémzmk
`ififfiaze E2: is mamas: mm ammims sum ££s'§s‘:ais®§e:<§% mwaw ma mm: agsgxéfisxafian as‘ gasaiemt. E? gem ska
`mi §$.é3‘%‘-§i%%‘§ ma; mssmmé
`M £33.. §3e.*&:«3z'se1 asssé? my me: m me xx
`gsszzssxmw £i§’§i§ft3!‘ amsfim gewsr &as§m§ssss%¢:2n;,
`my iwfisfi $9: $§“3’§?§3‘§£%‘§€}§‘3
`:3? gzmmmfiszm m
`&mwmmm$m sr
`
`Ym §§’€€%:3:‘2”s‘§%i‘E£}§‘3
`
`§§‘£It-"§r‘§%‘Z§®£§ $3; gm: 3:: Ma mm m?§ izg g.-::§§@¢;$: is; gm fig mmfim mas:
`
`*§.
`
`3'.
`
`ii
`
`smsarfi,
`
`fie.
`
`“fins i::%‘s.*:z<§2§mé<ass mi 33$ mm «as fie §:‘az‘§i$i‘3 mafifismfiafiy ta 3%: sexism aiimsw wmw gm
`§*‘e\ma§e::ss*;s :3?
`m {§
`$§§E§ szsrié‘ §%~ §3s°§§*a::§s $§€§. £3 §;.¥,$.€.2 fifizéa}. fimmxfia
`‘§*z§%—s3esmr::~:ré‘.ms<23s may §s<§iz§a:;§£Im€§ mmmmmw
`fixfiwvwwmwmmmmmwmfimfim §?§m§s:2£§3s2?§§3§8:?z§a§§ms§§&
`fimmefimm m§£$y$mms%wm§§sm&§‘m , m a swfirwzs assess, if:
`gxmsmfiskg
`ésra 2:. asmssé. mmfsmw, w $€§5‘?$§§“§§§?$:§.§‘s‘§ fiéémyiai. imwsfiag émmwm gm
`agzmiag massages: in: ma azsszsmas af
`;°:§§:‘:s§ai§‘£3:?s&
`waz, Ex: 3 fiemssfiar 2:?
`39.. ;°$».°:s:ss’fi ifs fézis
`21:‘? raatmfis my Em £§a@:a3z:ss&fi, as as
`mi3m§§§:§*2g & 3‘®2§'&5€§§§ immixseim fia § . M wémm M mamsé mixing, wmgs firm
`mg
`£i$&$§$§¥3§‘$::)38
`fim mm wi*§<.= mmszfi the fives
`S‘§i3i‘.§fi? <3?‘ 32$
`‘
`&;*:im.~:«*§s%::~i&*2:s:o§ms'~s5:$s2‘:eas:g*i24§ fimmm, R38:,S%:?£§§§$'sé3 nae, éegs § ’¢¥&e
`mmmmmsmmmmmmnmmxmw-mwkmawmm Rmmugséssfisafi
`fifiwmém mi: 1523 sm§s§'xsaé 22> mmsy wfiéi me mqsgésmwsm sf am Wwsy
`af %§?<<§, ssse
`mm:%::%<<:i, mmmé we 5 %£.$.{';~, :§$2&€m}.
`in
`mg isms}: ma $33.-éafini Qmmmfim
`$Y A mzazsvzi méaé-sssté in as:
`$3
`Enwnafixwsaé §::§$ms rsffiw
`$233 a:g=s‘§ses:sx 3%‘ z1s§s':»3z‘£i:§ 333$}? bx . m a
`§‘§*:;¢i§§ §sm¥§§~s3s;::§:m Fmgsmg m%, ;3§m;¢:.:&§‘2§. $22) $3 Wm '§3~{}%2i>§I?&?§’§§3’§ “§“;*m§:sr.
`S, Asmfici $32 %$%§asj¢s:im§ss$:?m«zx3€£§2s—s§3a§*§:e:&?sxi&:&m{ ass mgéém um &2a23s:s§§~ze:*‘§w'2a;~a§
`i3w5§"ss:«’§%‘ fix gsxsms 2:3? .§>éa§m;s§
`meaeémr {£8 §§.$.e:.‘;. ‘gm
`‘ism’
`msmgam is
`m
`§z%$:§;»“ sine: gs}: 153%?‘ ::~3~:‘&{s}}.
`V
`a&&s‘m:§§§&as$.R%§%§3£§:mn§$i§a§:2§',.
`§»ws*3€m:§‘3§i>§s~2s§smme3€r$s2a:z§s:§&§§§ms$§%,
`iZ§w.m%m§
`<39“ ?:.§&$'3>§:z° siémfitézreg a$:s§‘ér;§ we imgmcfim £2?! sszsmaia msssimfimi izy G$§z am
`»:§§"§°ssa:‘. s§§§£§¢;};°& §§§%§ iss mmmnmaé mwmmmm in mm £ $fi&Rfi
`gsa-m:&mx uaszfi sfirfimwsa, aims: m§%$§?i3§ :2? $3 %;.§..«.?.‘=§<£‘;‘3»; §§&i}oi gm
`Sa.§e::é~2 zfiisaémasm am
`ha
`En
`$28
`§‘a~,§s§§&§%es~%x gcwmiragg
`22$ :‘ezm3§z“.§§.: 533$‘ Viiséa
`§:;:§,m§ am‘ am:
`mimrmai‘ gf §.a,¢ €333 at
`fimfimaaas shafi M:
`as mm:§ m smka :i=:s§s:'€$:§rsa§is;:sse;$ amvé. imfivéiiam.
`is: ms §5%;s§3¥§$ sfia:
`5% €\8:fe:3§'i$ §‘:¥;m ithés $3§?ae.§s§s¥§ §2§m€::§:’§;§:3 my mg mmm. m 3 §'m§E§é“:<=3
`wwr ;mi3i§{:.&§§>§°s 35’ $3922 a§3;:£€mms gzassmsasai m '33 $3.-$3. ’%.°&£{§:«} m’ é$aasas::§::a 22%‘ a mfiam
`mrszsmf fie $2’? %;§.S£.2. *é§.'§—, £3-‘§se'€§%s3%‘;
`ss
`£m§ im ::§'m::sm:§'. sgfim its 5% iimfiniaiiam: iii :§?
`2393: *§.'§»€~, as a mfiaa
`m M gzeaficséis: %%°*:€°§e
`.me>s:=s~<§ was fiiefi $2: $2} msgfiémms: &%:‘§‘§=§s2§‘s
`mmem
`win «mm ma mwmmm %§s‘$?8’€%1駰§°:“s§%‘Ee‘e‘§m§ mas mm $;:§§§::a§m'§ is
`§*-§'§Ei€?3?i!$%E?§ §s§< aaéfiw >2: ggswwzasi
`ass“:
`amass $3 g3i.§§?§s: §s‘§$§§%‘m§€>§’s <33‘ am
`.
`§§%éa2¢;"s§.
`go} 5 §§§€f(3g‘f§§’ ggggs,
`$3;§§s§$‘.-“8 as? ywrcfis my‘ me fiiafimask as as mazmza
`‘§2's‘.s$‘3‘i
`saw w&§' §~§‘ me i§$§3“S‘{} §<m>:>xm2s &%i?&§‘§ 5% we véaigifim :2: ;ms‘és§::~‘Ea§
`
`2?.
`
`§.
`
`$§.
`
`fig
`
`0785
`
`0785
`
`

`

`Bee Cede: "i”RACi(i.REQ
`
`Beeument Description: Tracirflne Request
`
`PTO/ASA/424 (0344)
`
`‘SERTTFTCATTGN ANS REQUEST FGR PREORTTTZEQ EXAMTNATTGN
`
`UNQER 3"? CFRi.iG2(e}(i3agetc>i1)
`
`‘
`
`First i\iarne<i
`inventor:
`Titie of
`invention:
`
`Neriprcivisicinai Appiicaticen Nurnber (if
`‘ known):
`Afldrew Aaheampgng
`ii/IETHQDS OF PRO‘V'iDii\iG THERAPEUTKI EFFECTS USENG CYCi_.QSPC)Rii\i COB./iPQNEi\iTS
`
`APPLTCANT HEREBY {2ERTiFiE$ THE FQLLQWENQ ANS REQiJEST$ PREQRETEZEEB EXAMENATEQN FQR
`THE ABGVE-EDENTEFEEQ APPLECATEON.
`
`i. The processing tee set terth in 33’ CPR i.i‘}’{i){’i), the prioritized exarniriatien fee set terth in
`3? CFR i.’i7(e), and it not aiready paid, the pubiieatien tee set forth in 37 CPR ’i.18{d) have
`been fiied with the request. The basis fiiihg fee, search fee, and examination fee are fiied with
`the request er have been aiready been paid.
`i understand that any required excess ciairns fees
`or appiieatien size fee ti‘ttiS‘i be paid for the appiibatien.
`
`i understand that the appiieatien may not contain, or be amended te contain, more than four
`independent ciaims, more than thirty‘ tetai eiairns, er any rnuitipie dependent biairns.
`
`3. The appiieabie box is checked beiow:
`
`Qriinai Aiieatien Track fine - Prieritized Exarninatien under ‘re "i.‘it.i2 } }
`
`i,
`
`(a) The appiicatipn is an erigihai rienprevisiehai utiiity appiieatien fiied under 35 iJ.S.C. ’i’i‘i(a).
`This certification and request is being fiied with the utiiity appiicatidn via EFSA/Veb.
`mars---
`
`(b) The appiicatieri is an eriginai nenprevisienai piant appiieation fiied under 35 tJ.S.C. ‘i‘ii(a).
`This certification and request is being fiied with the piant appiicatien in paper.
`
`ii. An executed inventdr’s oath or deciaration under 37 CPR 1.63 er 3?’ CFR 1.64 for each
`inventer, gr“ the appiieatien data sheet meeting the eendiiiehs specified in 37 CFR t.53(t)(3)(i) is
`fiied with the appiieatien.
`
`E
`
`‘
`
`I Reuest fer Continued Exarninatien ~ Frieritized Examination under 1.192 ; ;
`
`.
`
`'
`
`A request for continued exarninatioh has been fiied with, or prior to, this term.
`if the appiieatien is a utiiity appiicatien, this certification and request is being tiied via EF£i‘§—\:'\ieb.
`The appiieatien is an originai nehprevisienai utiiity appiieatieh iiied under 35 U.S.C. ‘i’ii(a), er is
`a naiieriai stage entry under 35 Li.S.C. 371.
`. This certitieatipri and request is heing tiied prior to the rnaiiihg of a first Office aetien respensive
`to the request for continued examination.
`Ne pridr request fer continued examination has been granted prioritized examination status
`under 37 CFR ’i.‘iO2(e}(2}.
`
`{Laura i... Wine!
`
`Dmuarch 2i, sets
`Practitioner
`i Re istration i\i-urnber
`
`This form rnusf be signed in £2Cz:0rdaric.‘£3 -.4/.-'t.ii 3.7 CFR 1.33. See 37 CFR’ 1.4(:)') for signature requrrerrzerlts and certificaficnns.
`Note:
`Submit multiple farms if more than one 3;’nature is required. *
`
`‘
`
`forms are submitted.
`
`0786
`
`0786
`
`

`

`Privacy Act Statement
`
`The Privacy Actof1t}?4 (F25... $3~5?9) requires that you be given certain information in connection with your
`stibrnission of the attached form related to a patent appiication or patent. Accordingly, pursuant to the requirements of
`the Act, please
`advised that: (1) the generai authority for the coliection of this information
`35 U.S.C. 2(h)(2); (2)
`furnishing of the information soiicited is voluntary; and (3) the principai purpose for which the information is used by the
`US. Patent and Trademark Office is to process and/or examine your submission reiated to a patent appiicatioh or
`patent.
`if you do not furnish the requested information, the US. Patent Trademark Office may not be ahie to
`process and/or examine your submission, which may resuit in termination of proceedings or abandonment of the
`appiication or expiration of the patent.
`
`information provided by you in this form wiil be subject to the foiiowing routine uses:
`
`1.
`
`_CI‘-
`
`The information on this form will be treated cohfidentiaiiy to the extent aliowed under the Freedom of
`information Act (5 tJ.S.C. 582) and the Privacy Act (5 tJ.S.C 552a). Records from this system of records may
`be disclosed to the Department of Justice to determine whether disciosure of these records
`reduired by the
`Freedom of information Act.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tnouhai, including disciosures to opposing counsei in
`course of
`settiement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a iviernher of Congress submitting a
`request invoiving an ihdividuai, to whom the record pertains, when the individuai has requested assistance from
`the Member with respect to the subject matter of the record.
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
`need for the information in order to perform a contract. Recipients of information
`be required to compiy
`with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 USC. 552a(m).
`A record reiated to an internationai Appiicatioh filed under the Patent Cooperation Treaty in this system of
`records may he disciosed, as a routine use, to the international Bureau oi’ the Worid lnteiiectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another tederai agency for purposes
`of Nationai Security review (35 USC. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`2t8(c)‘).
`A record from this system of records may be disciosed, as a routine use, to the Administrator, Generai
`Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency’s
`responsipiiity to recommend improvements in records management practices and programs, under authority of
`44 tJ.S.C. 2904 and 2906. Such disciosure shaii be made in accordance with the GSA reguiatiohs governing
`inspection of records for this purpose, and any other reievant (i'.e., GSA or Commerce) directive. Such
`disciosure shali not he used to make determinations about individuais.
`
`A record from this system of records may be disoiosed, as a routine use, to the puhiic after either puoiication of
`the appiication pursuant to 35 U.S.C. ‘t22(b) or issuance of a patent pursuant to 35 tJ.S.C. ‘E51. Further, a
`record may he disciosed, subject to the limitations oi’ 3.7 CFR 1.14, as a routine use, to the puhiic if the record
`was filed in an appiication which hecame abandoned or in which the proceedings were terminated and which
`appiication is referenced by either a published appiication, an appiication open to pubiic inspection or an issued
`patent.
`be disciosed, as a routine use, to a Federai, State, or iocal iaw
`A record from this system of records
`enforcement agency, tithe USPTO becomes aware of a vioiation or potentiai vioiation oi iaw or reguiation.
`
`Paec 2
`
`0787
`
`0787
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`.
`.
`Application Data Sheet 37 CFR 1.76
`
`Attotttev Docket Ntttttttt
`_
`_
`Atttttattott Nttttttet —
`
`Title of Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`document may be printed and included in a paper filed application.
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`
`Secrecy Order 37 CFR 5.2
`
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`D Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`
`Inventor Information:
`
`Inventor
`
`1
`
`Legal Name
`
`Fatttttvttattte
`ttttttttttttttttttt
`IE1
`Residence Information (Select One) @ US Residency 0 Non US Residency 0 Active US Military Service
`
`Attttttsst
`
`
`Mailing Address of Inventor:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Inventor
`2
`
`
`
`Legal Name
`Prefix Middle Name
`Family Name
`suffix
`_
`Residence Information (Select One) @ US Residency O Non US Residency 0 Active US Military Service
`City
`StatelProvince
`Country of Residence
`US
`
`
`
`
`
`
`
`
`Address 1
`Address 2
`
`
`City
`CA
`us
`89158-4397
`Postal code
`
`
`Mailing Address of Inventor:
`
`
`
`
`
`3
`Inventor
`
`
`
`Legal Name
`
`Prefix Middle Name
`Family Name
`suffix
`
`
`
`
`
`
`
`
`Residence Information (Select One) @ US Residency 0 Non US Residency 0 Active US Military Service
`
`
`
`
`EFS Web 2.2.11
`
`
`
`0788
`
`0788
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`.
`.
`APP'i<=a“°n Number —
`
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`Title of Invention
`
`US
`CA
`Country of Residence
`State/Province
`Newport Beach
`City
`
`
`
`Mailing Address of Inventor:
`
`Addressf
`
`
`
`
`
`Inventor
`4
`
`
`Legal Name
`
`Prefix Middle Name
`
`Family Name
`
`suffix
`
`Residence Information (Select One) (9 US Residency 0 Non US Residency 0 Active US Military Service
`
`
`State/Province San Clemente
`City
`CA
`Country omesidencé
`
`Addressf
`Addressz
`City
`CA
`
`
`Mailing Address of Inventor:
`
`
`
`
`
`
`Us
`
`
`
`
`
`
`
`All
`
`Inventors Must Be Listed - Additional
`
`Inventor
`
`Information blocks may be generated within this form by selecting the Add button.
`
`Correspondence Information:
`
`Enter either Customer Number or complete the Correspondence Information section below.
`For further information see 37 CFR1.33(a).
`
`|:| An Address is being provided for the correspondence Information of this application.
`
`Customer Number
`
`051957
`
`Email Address
`
`Patents_ip@A||ergan.com
`
`Application Information:
`
`
`Filing By Reference:
`
`Title of the Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`Attorney Docket Number 17618CoN6CoN1(AP)
`
`Small Entity Status Claimed
`
`|:|
`
`Application Type
`
`Nonprovisional
`
`Subiectmatter
`Total Number of Drawing Sheets (if any) — Suggested Figure for Publication (if any) ‘
`
`EFSWeb 2.2.11
`
`0789
`
`0789
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`.
`.
`Application Data Sheet 37 CFR 1.76
`
`Attotttev Docket Ntttttttt
`_
`_
`Atttttattott Nttttttet —
`
`Title of Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`
`
`Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage |nformation” and "Foreign Priority |nformation”).
`
`For the purposes ofa filing date under 37 CFR 1.53(b), the description and any drawings ofthe present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR1.57(a).
`
`Application number of the previously
`filed application
`
`Filing date (YYYY-MM-DD)
`
`Intellectual Property Authority or Country
`
`Publication Information:
`
`|:| Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`publication at eighteen months after filing.
`
`I hereby request that the attached application not be published under
`Request NOII t0 PLlbIISI1.
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below.
`If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`Please Select One:
`Customer Number
`
`@ Customer Number
`
`0 US Patent Practitioner 0 Limited Recognition (37 CFR 11.9)
`
`051957
`
`
`Domestic BenefitlNationa| Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120,121, or 365(c) or indicate National Stage
`entw from a PCT application. Providing this information in the application data sheet constitutes the specific reference required
`by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the application number blank.
`
`Application Number
`
`Continuity Type
`Continuation of
`
`Prior Application Number
`13961828
`
`Filing Date (YYYY-MM-DD)
`2013-08-07
`
`Prior Application Status
`
`Patented
`
`Application
`
`.
`
`.
`
`Prior Application
`
`Filing Date
`
`ISSUE Date
`
`13961828
`
`Continuation of
`
`11897177
`
`2007-08-28
`
`8618064
`
`2013-12-31
`
`Prior Application Status Abandoned
`
`EFSWeb 2.2.11
`
`0790
`
`0790
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Title of Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`
`
`Application Data Sheet 37 CFR 1.76
`.
`.
`APP'1<=a11°11 Number —
`
`
`Application Number
`11897177
`
`Prior Application Status
`Application Number
`
`
`
`Continuity Type
`
`Prior Application Number
`
`Filing Date (YYYY-MM-DD
`
`)
`
`
`
`Filing Date (YYYY-MM-DD)
`
`Additional Domestic Benefit/National Stage Data may be generated within this form
`by selecting the Add button.
`
`
`
`Foreign Priority Information:
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.5_5(d). When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX)I the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(h)(1) and (2). Under the PDX program, applicant bears the ultimate
`
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).
`
`Add button.
`
`Application Number
`
`CountryI
`
`Filing Date (YYYY-MM-DD)
`
`Access Code‘(if applicable)
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`Applications
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`|:| 16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`Authorization to Permit Access:
`
`IZ Authorization to Permit Access to the Instant Application by the Participating Offices
`
`EFSWeb 2.2.11
`
`0791
`
`0791
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Title of Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`Application Data Sheet 37 CFR 1.76
`.
`.
`APP'i<=a“°n Number —
`
`
`
`
`)If checked, the undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO ,
`
`the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the World Intellectual Property Office (WIPO),
`and any other intellectual property offices in which a foreign application claiming priority to the instant patent application
`is filed access to the instant patent application. See 37 CFR 1.14(c) and (h). This box should not be checked if the applicant
`does not wish the EPO, JPO, KIPO, WIPO, or other intellectual property office in which a foreign application claiming priority
`to the instant patent application is filed to have access to the instant patent application.
`
`
`
`In accordance with 37 CFR 1.14(h)(3), access will be provided to a copy of the instant patent application with respect
`to: 1) the instant patent app|ication—as—fi|ed; 2) any foreign application to which the instant patent application
`claims priority under 35 U.S.C. 119(a)—(d) if a copy of the foreign application that satisfies the certified copy requirement of
`37 CFR 1.55 has been filed in the instant patent application; and 3) any U.S. app|ication—as—fi|ed from which benefit is
`sought in the instant patent application.
`
`In accordance with 37 CFR 1.14(c), access may be provided to information concerning the date 0 ffiling this Authorization.
`
`Applicant Information:
`
`
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`Applicant
`
`1
`
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who othen/vise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. lfthe applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who othen/vise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`0 Legal Representative under 35 U.S.C. 117
`
`0 Joint Inventor
`
`O Person to whom the inventor is obligated to assign.
`
`0 Person who shows sufficient proprietary interest
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`
`
`
`
`
`
`Name of the Deceased or Legally incapacitated Inventor :
`
`If the Applicant is an Organization check here.
`
`Organization Name
`
`Anergan’ Ina
`
`Mailing Address Information For Applicant:
`
`Address 1
`
`Address 2
`
`2525 Dupont Drive, T2-7H
`
`Phone Number
`
`(714) 246-6996
`
`Fax Number
`
`(714)246-4249
`
`EFS Web 2.2.11
`
`0792
`
`0792
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`.
`.
`Application Data Sheet 37 CFR 1.76
`
`Attotttev Docket Ntttttttt
`_
`_
`
`Atttttattott Nttttttet — Title of Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`Email Address
`
`Patents_ip@A||ergan.com
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`
`
`Assignee Information including Non-Applicant Assignee Information:
`
`Providing assignment information in this section does not subsitute for compliance with any requirement of part 3 of Title 37 of CFR to
`have an assignment recorded by the Office.
`
`Assignee
`
`1
`
`Complete this section if assignee information, including non—app|icant assignee information, is desired to be included on the patent
`application publication . An assignee—app|icant identified in the "Applicant |nformation" section will appear on the patent application
`publication as an applicant. For an assignee—app|icant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`Prefix
`Middle Name
`
`Family Name
`
`|:|
`Suffix
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`Addtttss2
`Cttv ——
`Cttttttttvt——
`t’tt°ttttNtttttttttt —
`—
`Email Address
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`selecting the Add button.
`
`Signature:
`
`NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and
`certifications.
`
`
`
`Additional Signature may be generated within this form by selecting the Add button.
`
`t<tttttStt'tttt°ttNtttttttttt
`
`686“
`
`EFSWeb 2.2.11
`
`0793
`
`0793
`
`

`

`PTO/AIA/14 (12-13)
`Approved for use through 01/31/2014. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`.
`.
`Application Data Sheet 37 CFR 1.76
`
`Attotttev Docket Ntttttttt
`_
`_
`
`Atttttattott Nttttttet — Title of Invention
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.11
`
`0794
`
`0794
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to
`a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that:
`(1) the general authority for the collection
`of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is
`used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent.
`If you do not
`furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552)
`and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine
`whether the Freedom of Information Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or
`administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
`
`3.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an
`individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of
`the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in
`order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed,
`as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent C o o p eration Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security
`review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee,
`during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records
`management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the
`GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant
`to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were
`terminated and which application is referenced by either a published application, an application open to public inspections or an issued
`patent.
`
`